Ixempra
Ixempra Uses, Dosage, Side Effects, Food Interaction and all others data.
Ixempra is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixempra is administered through injection, and will be marketed under the trade name Ixempra. Ixempra is a semisynthetic analogue of epothilone B. It has a lactone–lactam modification that minimizes susceptibility to esterase degradation.
Trade Name | Ixempra |
Availability | Prescription only |
Generic | Ixabepilone |
Ixabepilone Other Names | Aza-epothilone B, Azaepothilone B, Ixabepilone |
Related Drugs | Arimidex, Ibrance, Femara, Xeloda, Herceptin, Lynparza |
Weight | 15mg, 45mg, |
Type | Injection, Intravenous Powder For Injection |
Formula | C27H42N2O5S |
Weight | Average: 506.7 Monoisotopic: 506.281443634 |
Protein binding | 67-77% |
Groups | Approved, Investigational |
Therapeutic Class | |
Manufacturer | Bristol-myers Squibb Pvt Ltd |
Available Country | India, United States, |
Last Updated: | September 19, 2023 at 7:00 am |
Uses
Ixempra is a microtubule inhibitor administered in combination with capecitabine or alone in the treatment of metastatic or locally advanced breast cancer that has shown inadequate response to taxanes and anthracyclines.
Investigated for use/treatment in breast cancer, head and neck cancer, melanoma, lung cancer, lymphoma (non-hodgkin's), prostate cancer, renal cell carcinoma, and cancer/tumors (unspecified).
Ixempra is also used to associated treatment for these conditions: Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer
How Ixempra works
Binding of Ixempra to beta-tubulins (e.g. beta-III tubulin) stabilizes microtubules. Microtubules are essential to cell division, and epothilones therefore stop cells from properly dividing. Like taxol, Ixempra binds to the αβ-tubulin heterodimer subunit. Once bound, the rate of αβ-tubulin dissociation decreases, thus stabilizing the microtubules.
Food Interaction
- Avoid grapefruit products. Grapefruit inhibits the CYP3A4 metabolism of ixabepilone, which may increase its serum concentration.
- Avoid St. John's Wort. This herb induces CYP3A metabolism and may reduce serum levels of ixabepilone.
[Moderate] GENERALLY AVOID: Grapefruit juice may increase the plasma concentrations of ixabepilone.
The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.
MANAGEMENT: Patients treated with ixabepilone should avoid the consumption of grapefruit or grapefruit juice.
Ixempra Disease Interaction
Major: cytopenia, liver dysfunctionModerate: cardiovascular, neuropathy
Half Life
52 hours
Elimination Route
Mostly fecal and some renal.
Innovators Monograph
You find simplified version here Ixempra